Cartesian Therapeutics公司今日披露了其核心管线的最新进展：针对Descartes-08用于治疗重症肌无力的III期Aurora临床试验，关键数据预计将在2027年第一季度出炉。与此同时，该公司计划于2027年年中向监管机构提交生物制品许可申请（BLA）。
这一时间表标志着这家生物技术公司在该适应症领域的研发工作迈入了关键阶段。重症肌无力是一种罕见的慢性自身免疫性疾病，会导致患者肌肉无力、疲劳，严重影响生活质量。Descartes-08作为一种创新的细胞疗法，旨在通过调节免疫系统来改善患者症状。
公司方面强调，Aurora试验的顺利推进是验证Descartes-08安全性与有效性的重要里程碑。若试验数据积极，BLA的及时提交将有望加速该疗法上市进程，为患者提供新的治疗选择。目前，市场正密切关注这一试验的后续动态。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.